header logo image


Page 30«..1020..29303132..40..»

Archive for the ‘Personalized Medicine’ Category

New resources in precision medicine that every doctor should know about – MultiBriefs Exclusive

Thursday, January 30th, 2020

Precision medicine, or personalized medicine as it is sometimes referred to, is a most significant and promising healthcare trend. The National Institutes of Health (NIH) defines precision medicine as an individualized plan that uses a patient's genetic makeup and their environment and lifestyle to deliver the right preventative advice or targeted disease treatment.

For example, precision medicine as it applies to cancer treatment might encompass:

The NIH has also started an ambitious research program designed to advance the study and applications involved in precision medicine, which can have positive ramifications for the future of medicine as a whole. The Precision Medicine Initiative is geared toward learning how genetics, environment, and lifestyle can help determine the best approach to prevent or treat disease.

Through the initiative, for example, scientists at the National Cancer Institute hope that further study of the disease's genetics and biology will lead to better life-extending treatments. The initiative's All of Us Research Program is also using the health data of approximately 1 million volunteers to study many other diseases, and improve prevention, diagnosis, and treatment stats.

Precision medicine has such a huge range of potential applications that the sky is literally the limit in terms of how it may help doctors treat virtually any disease in the future.

But right now, there are several exciting developments that you, as a physician or hospital administrator, should know about and investigate further to see if they may be appropriate for your patients' needs. These developments include:

The Centers for Disease Control has highlighted the fact that that a new small molecule drug, ivacaftor, is improving the outcomes of cystic fibrosis (CF) patients by closely targeting the specifics of why an individual patient has CF, as opposed to treating its symptoms.

Early administration of this therapy has greatly reduced the need for inpatient hospital stays and allowed patients to improve.

The CDC has also highlighted cascade screening, which means a healthcare team contacts the family members of patients with a range of conditions to interview them about and inform them about the hereditary implications of the illness they may all eventually deal with.

Then, patients who wish to be screened for genetic markers or a disease itself can do so. The information that doctors learn from a patient's relative can then be applied to treating the original patient. It's extremely important to take issues of consent and privacy into account in terms of this approach, but if done right, the benefits to patients and their families can be invaluable.

MD Anderson has set up a personalized care therapy resource website, through which any doctor can look up information on a diagnosed genetic marker and find cutting-edge info on clinical trials, disease mutations, and tumor profiling. Patients working with their doctors to better understand their conditions can use the website, too.

It's vitally important to keep up with precision medicine developments in your specialty fields and apply what is available for you as a physician or administrator right now. With precision medicine, you lengthen a patient's odds for a better outcome in so many potential ways. Just as important is that precision medicine can change the way your patients view their disease(s).

Lisa Mulcahy is an internationally established health writer whose credits include the Los Angeles Times, Redbook, Glamour, Elle, Cosmopolitan, Health, Good Housekeeping, Parade, Woman's Day, Family Circle and Seventeen. She is the author of eight best-selling books, including "The Essentials of Theater," an Amazon No. 1 new release.

Her Contemporary Authors biography is available here.

Read more:
New resources in precision medicine that every doctor should know about - MultiBriefs Exclusive

Read More...

Research Presented at LINC Suggests the Profusa Lumee Oxygen Platform May Improve Clinical Management of Patients with Critical Limb Ischemia -…

Thursday, January 30th, 2020

LEIPZIG, Germany and EMERYVILLE, Calif., Jan. 30, 2020 /PRNewswire/ --Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced research findings that suggest the company's Lumee Oxygen Platform may help improve the clinical management of patients with critical limb ischemia (CLI) who are undergoing endovascular revascularization treatment (EVT). The data, from a recent post-market clinical study called OMNIA (Oxygen Monitoring Near Ischemic Areas), were detailed in a series of presentations at the Leipzig Interventional Course (LINC) in Leipzig, Germany.

The Lumee Oxygen Platform is a tiny, injectable tissue-integrated biosensor with an intelligent data platform intended for continuous, real-time monitoring of tissue oxygen levels.

"Performing revascularization in patients with critical limb ischemia is standard practice, but the tools surgeons and interventionalists typically use to gauge effectiveness of the procedure are not ideal," said Marianne Brodmann, M.D., interim head of the Clinical Division of Angiology, Department of Internal Medicine, at Medical University inGraz, Austria. "These research findings from OMNIA suggest that continuously measuring tissue oxygen may result in better outcomes for these patients."

CLI is a serious form of peripheral artery disease (PAD), a condition that affects more than 200 million people worldwide and results in the narrowing of blood vessels and reduced blood flow to the lower limbs. Decreased tissue oxygen levels in the lower limbs of PAD patients can lead to disabled walking, or in more advanced cases, gangrene and amputation. CLI can result in severe pain in the feet or toes, even while resting.

OMNIA, a multicenter trial of the Lumee Oxygen Platform, monitored tissue oxygen levels in the affected limbs of 35 CLI patients who underwent EVT procedures, which are designed to clear obstructed arteries. Study participants were injected with four Lumee biosensors, three in the foot and one as a reference sensor in the arm. OMNIA collected measurements of oxygen throughout the revascularization process (with measurements performed before, during, and one, three, six, and twelve months post-procedure). OMNIA also recorded traditional hemodynamic metrics, including ankle-brachial index and toe-brachial index, and clinical assessments of wound healing at each follow-up visit.

The OMNIA data presented by Brodmann showed that increases in tissue oxygen during EVT were significantly higher in patients who experienced wound healing than in those who did not (p<0.01). In addition, tissue oxygen levels during revascularization were a better predictor of wound healing than traditional clinical measures, such as ankle-brachial index or toe-brachial index (p=0.59 and p=0.14, respectively).

"These findings show the importance of further investigating how continuous tissue oxygen measurements may satisfy an unmet clinical need to objectively evaluate how the increases in blood flow offered by EVT actually translate into nutritive oxygen delivery to the injured tissue," added Brodmann.

Martin Werner, M.D., an angiologist at Hanusch Hospital in Vienna, noted that traditional angiography during EVT does not sufficiently measure microvascular blood flow, a special concern for people with diabetes who may have microvascular impairment. He presented results of a retrospective classification analysis from OMNIA in which continuous oxygen traces measured by the Lumee Oxygen Platform were analyzed throughout EVT. Findings showed that oxygen changes between discrete time points, specifically start and end of EVT, may not be predictive of wound healing, but dynamic changes continually assessed throughout the procedure were.

"These results indicate that continuous measurements of blood flow in the foot during EVT may reveal factors that provide clues to treatment outcome that would have been missed if only measured at the start and end of the procedure," said Werner.

Stephen Kanick, Ph.D.,data science lead for Profusa, presented data from OMNIA that evaluated how Lumee biosensors assess long-term tissue viability following EVT treatments in patients with CLI. Results showed that patients who improved showed larger oxygen increases after EVT and maintained larger oxygen values at a three-month follow-up compared to patients who did not improve.

Miguel Montero-Baker, M.D., vascular surgeon and associate professor in the Division of Vascular Surgery and Endovascular Therapy at Baylor College of Medicine in Houston, discussed how tissue oxygen measured before, during and after EVT can be combined to provide a more accurate predictor of patient healing. According to Montero-Baker, "The Lumee Oxygen Platform gives us insights we have not had before about how CLI patients are responding to treatment."

"These findings from OMNIA affirm the emerging role of injectable biosensors in informing the treatment of patients with limb-threatening ischemia," said Ben Hwang, Ph.D.,chairman and CEO of Profusa. "Being able to monitor biochemical data such as tissue oxygen on a real-time basis may mean the difference between effective interventions and a catastrophic worsening of the condition."

Profusa's LumeeOxygen Platform and second-generation product, the Wireless LumeeOxygen Platform, are CE (Conformit Europenne) marked for use in the European Union. In the U.S., the Wireless Lumee Oxygen Platform is an Investigational Device limited by federal law to Investigational Use.

About ProfusaBased in Emeryville, Calif., Profusa is a digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors who share the long-term goal of improving health and well-being for patients worldwide. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians trust and rely upon. These data may allow people to act as an active and educated participant alongside their care team and understand how their choices and decisions impact health and well-being, day-in and day-out.

"LUMEE", "PROFUSA" and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.

For more, visithttps://profusa.com.

AbouttheLumeeOxygen PlatformProfusa's first clinical offering, the LumeeOxygen Platform, and the next-generation Wireless LumeeOxygen Platform, which are CE marked for use in the European Union, are indicated for use in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from monitoring. The Lumee Oxygen sensor provides an opportunity for continuous and long-term monitoring of oxygen changes in subcutaneous tissue. After a single injection, measurement thereafter is obtained non-invasively using an optical reader. In contrast to external pulse oximeters, which measure oxygen bound to the hemoglobin in larger blood vessels, the LumeeOxygen Platform measures dissolved oxygen at the tissue level in the fluid that bathes our cells.

Contact: Sylvia ArandaW2O pure424-201-9464saranda@purecommunications.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/research-presented-at-linc-suggests-the-profusa-lumee-oxygen-platform-may-improve-clinical-management-of-patients-with-critical-limb-ischemia-300995818.html

SOURCE Profusa, Inc.

View original post here:
Research Presented at LINC Suggests the Profusa Lumee Oxygen Platform May Improve Clinical Management of Patients with Critical Limb Ischemia -...

Read More...

Transforming healthcare practices and patient care in the digital era – MedCity News

Thursday, January 30th, 2020

As we herald in the new decadeone that will be entirely driven by digital transformation and the agile integration of innovative technology at a rapid paceenterprises across the board are re-evaluating their internal and external operations from the ground up. In the past decade, we have witnessed new technologies come to lifefrom cloud and edge capabilities, blockchain, to 5G connectivity and beyond. Industries are fighting tooth and nail to bring these technologies first-to-market, and oftentimes expand upon the previously-determined boundaries of what purposes these technologies were built to serve.

Were at a vital turning point as we enter 2020, where organizations across all industries must not only continue to integrate innovative technology into their internal and external operationsthey must reimagine their businesses entirely and rebuild their foundational infrastructure to adopt agility and the ability to pivot on a dime, for when the next big technological advancement undoubtedly rises to the surface.

The healthcare industry is no different.

To date, the healthcare industry has been actively digitizing at a rapid pace. In fact, a recent study shows that a whopping 84 percent of U.S. based healthcare organizations utilize digital health records.

The benefits of this investment alone have been far-reaching. Those healthcare organizations that have switched to digital health records deliver better patient care, provide patients with better outcomes on an individual basis, improve the workplace experience for staff members, and even are able to offer cost-efficient healthcare servicesall in comparison to their non-digital counterparts.

Over the next decade, these organizations will not only continue to reap the benefits of their pre-existing digital transformation efforts but will begin to significantly invest in other next-gen technologies and capabilities to continue to bring new, innovative patient care solutions to the reshaping and hyperconnected healthcare ecosystem.

Digital Capabilities will BlossomThere have already been significant advancements in digital capabilities, beyond simply digitizing records. Healthcare leaders have successfully implemented other capabilities, such as remote and self-monitoring medical chatbots, smart pills, implants and more. Such innovation is a direct reflection of the highly-advanced levels of digitalization throughout the industry.

That being said, wider adoption of AI and automation has yet to be fully realized. In fact, only a mere 33 percent of U.S. healthcare organizations have adopted AI technology. Thats not to say that the ambition for adoption isnt there. Back in 2018, over half of healthcare professionals believed that by 2023 there would be widespread AI adoption throughout the industry.

Going into 2020, we expect to see these ambitions become fully realized. AI is becoming increasingly mainstream in all aspects of patient carefrom the overhaul of triage and administrative capabilities to diagnostics and beyond. It can then help doctors understand more about a patient, through the strategic analysis and activation of pre-existing patient data.

Personalized Medicine will ThriveOur experience is that more than two-thirds (75%) of life sciences and healthcare organizations can customize products and services to almost every single interaction. This is an amazing feat for the industry at largeespecially when considering the lack of AI investment to-date.

We will see these capabilities continue to grow in 2020, as personalized medicine becomes increasingly high-tech and data-driven. As AI becomes increasingly ingrained in the process of personalized and precise medicine, the personalized solutions that are developed will become smarter, more specific and more custom-tailored than ever previously imaginable.

Furthermore, in 2020 medical implants will become increasingly agile and be able to perform more functions to minimize patient input for treatment. Bioprinting tech will bring prosthetics and stent technology to new heights as wellas new materials and build processes become fully-realized. The aforementioned bio- and precision-tech will make medical implants significantly less invasive and safer than ever before.

While these personalized capabilities are certainly not new to the industry, a majority of Americans are not familiar with what personalized medicine even is. Additionally, those who are familiar express tend to express concern over the cost of personalized care, and increasingly other elements such as privacy and data concerns. As medical-tech and digital transformation further push personalized care to new heights, there will also be a significant effort to inform the public about what these solutions are, how they are beneficial to patients and how they can remain affordable as well.

The healthcare industry is at a significant turning point. While digitizing records has been a focal point for industry players in the past, investment in next-gen technology will become bolder and more widespread. AI will play an integral role in helping healthcare organizations take a leap of faith toward becoming fully-digital, hyper-connected and mass-personalized. Its an exciting time to work within the healthcare industry, and a hopeful time for patients who will have access to smarter, better and more personalized patient services at lower cost.

Photo: Andreus, Getty Images

See original here:
Transforming healthcare practices and patient care in the digital era - MedCity News

Read More...

Global Molecular Diagnostics Market is Likely to Surpass US$ 22.5 Billion by the End of Year 2025 – ResearchAndMarkets.com – Associated Press

Thursday, January 30th, 2020

DUBLIN--(BUSINESS WIRE)--Jan 30, 2020--

The Molecular Diagnostics Market Share & Global Forecast, By Application, Technology, End User, Regions, Companies report has been added to ResearchAndMarkets.coms offering.

Increasing prevalence of Infectious diseases such as Influenza, HPV, Hepatitis, HIV and Tuberculosis despite rise in sanitation practices globally. In the past, antimicrobials medicines were used to fight powerful infectious disease but slowly in todays time antimicrobial agent is not able to give the desired results because the problem of drug resistant occurs in many people across the world.

Nowadays, a new diagnostic procedure is being followed to fight infectious disease like molecular diagnostic test is very effective which is quite fast and precise. The number of cancer patients is increasing very fast, so it is believed that in the coming time the molecular diagnostic test market will be growing at rapid pace. Global Molecular Diagnostics Market is likely to surpass US$ 22.5 Billion by the end of year 2025.

There are various reasons that will propel the market growth in forecast year; rising incidence rate of infectious disease, increasing incidence rate of cancer of all type, increasing people awareness regarding molecular diagnostic, rapid technological growth, widely acceptance of personalized medicine, rising healthcare infrastructure, increasing healthcare per capita expenditure across the developed and developing nation, accuracy of diagnosis, growing population of cardiovascular and neurological disorder etc. In addition, increasing prevalence of genetic disorder will further boost the market in forecast period of time.

The report titled Molecular Diagnostics Market Share & Forecast, By Application (Infectious Diseases, Blood Screening, Oncology, Genetic Testing, HLA (Tissue Typing), Microbiology, Cardiovascular Diseases, Neurological Diseases, Pharmacogenomics and Others), By Technology (PCR, Transcription-Mediated Amplification (TMA), Hybridiazation (In-situ Hybridiazation & FISH), DNA Sequencing & NGS, Microarray and Others), By End User (Hospitals & Academic Laboratories, Clinics and Commercial Laboratories, Others), By Regions [United States, Europe (Expect Russia), India, China, Japan, Brazil, South Korea, Mexico, Russia and ROW], Companies (Roche, Abbott, Myriad Genetics, Qiagen, BioMrieux and Others) provides a complete analysis of Molecular Diagnostics Market.

Market Insight by Application

The report provides comprehensive analysis of molecular diagnostic test market by application into ten parts: Infectious Diseases, Genetic Testing, Blood Screening, Oncology, HLA (Tissue Typing), Microbiology, Neurological Diseases, Pharmacogenomics, Cardiovascular Diseases, and Others. This report also provides key opportunities market and specific factors are given by each application market.

Market Insight by Technology

Here the market is fragmented into six parts; PCR, Transcription-Mediated Amplification (TMA), Hybridiazation (In-situ Hybridiazation & FISH), DNA Sequencing & NGS, Microarray and Others. Besides, many factors are analyzed that influence the growth, challenges and opportunities of market in technological context.

Market Insight by End User

The report provides complete insight of market by End User segments: Hospitals & Academic Laboratories, Clinics & Commercial Laboratories and Others. According to the publisher, Hospitals & Academic Laboratories will hold the largest market in global molecular diagnostic test market in forecast period of time.

Market Insight by Regions

This report covers the complete regional profile by 10 geographical market; United States, Europe, India, China, Japan, Brazil, South Korea, Mexico, Russia and Rest of World (ROW).

Key Topics Covered:

1. Executive Summary

2. Global Molecular Diagnostic Market

3. Market Share - Global Molecular Diagnostics

3.1 By Application

3.2 By Technology

3.3 By Countries

3.4 By Companies

4. Application - Molecular Diagnostics Market

4.1 Infectious Diseases

4.1.1 Hospital Acquired Infections (HAI)

4.1.2 HIV / HCV Testing

4.1.3 STD Testing

4.1.4 HPV Testing

4.2 Blood Screening

4.3 Oncology / Cancer

4.3.1 Breast

4.3.2 Colorectal

4.3.3 Prostate

4.3.4 Others

4.4 Genetic Testing

4.5 HLA (Tissue Typing)

4.6 Microbiology

4.7 Cardiovascular Diseases

4.8 Neurological Diseases

4.9 Pharmacogenomics

4.10 Others

5. Technology - Molecular Diagnostics Market

5.1 PCR

5.2 Transcription-Mediated Amplification (TMA)

5.3 Hybridiazation (In-situ Hybridiazation & FISH)

5.4 DNA Sequencing & NGS

5.5 Microarray

5.6 Others

6. Region - Molecular Diagnostics Market

6.1 United States

6.2 Europe

6.3 India

6.4 China

6.5 Japan

6.6 Brazil

6.7 South Korea

6.8 Mexico

6.9 Russia

6.10 Rest of World (ROW)

7. End Users - Molecular Diagnostics Market

7.1 Hospitals & Academic Laboratories

7.2 Clinics and Commercial Laboratories

7.3 Others

8. Roche Diagnostics - Company Analysis

8.1 Merger & Acquisitions

8.2 Sales Analysis

9. Abbott Laboratories - Company Analysis

9.1 Merger & Acquisitions

9.2 Sales Analysis

10. Myriad Genetics - Company Analysis

10.1 Merger & Acquisitions

10.2 Sales Analysis

11. Qiagen - Company Analysis

11.1 Merger & Acquisitions

11.2 Sales Analysis

12. BioMrieuxs Inc - Company Analysis

12.1 Merger & Acquisitions

12.2 Sales Analysis

13. Market Drivers

13.1 Various Developments in the Molecular Diagnostics Landscape

13.2 Integral to Traditional Labs

13.3 Improved Assay / Test Efficiencies

13.4 Targeting Antibiotic Resistance

13.5 Next Generation Ultrasensitive Molecular Diagnostics

13.6 Increasing Investment in Genomics & Proteomics Research

13.7 Technological Advances in Molecular Diagnostics

13.8 Increasing Acceptance of the Personalized Medicine

13.9 Growing Molecular Diagnostics for Food Safety

14. Challenges

14.1 Dearth of Trained Professionals

14.2 Regulatory Issues

14.3 Various Factors Slowing Growth of Molecular Diagnostics

14.4 Reimbursement Capabilities

14.5 Quality Checkpoints, Awareness & Acceptance

For more information about this report visit https://www.researchandmarkets.com/r/j3on5s

View source version on businesswire.com:https://www.businesswire.com/news/home/20200130005474/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

More here:
Global Molecular Diagnostics Market is Likely to Surpass US$ 22.5 Billion by the End of Year 2025 - ResearchAndMarkets.com - Associated Press

Read More...

It’s All About the Data in 2020 and Beyond – HealthTech Magazine

Thursday, January 30th, 2020

1. Siloed Data Is an Opportunity Lost

Data of all types clinical, financial and operational remain siloed for reasons that range from interoperability issues to legacy systems. This becomes further complicated when redundancies are created through mergers (such as multiple electronic health record systems, enterprise resource planning solutions and enterprise imaging systems).

In addition, payers and providers alike continue to struggle with mining unstructured data for clinical and business insights. For example, the Centers for Medicare and Medicaid Services (CMS) calibrates payments to Medicare Advantage plans based on plan population health as determined through diagnosis codes that identify chronic conditions.

Patient conditions, however, are often not included in the codes captured on claims. As such, payers must conduct a tedious exercise each year to retrieve additional data, sometimes from printed medical charts, to fill in the gaps.

The bottom line: Unused data is an opportunity missed in an industry where resources are stretched increasingly thin, especially when it comes to advancing quality of care and establishing new revenue streams.

Precision medicine has been an extraordinarily important quest for the healthcare community. We are now, at long last, making steady and measurable progress in leveraging genomics to improve outcomes.

In cancer care, for example, it is becoming routine to analyze tumors for known gene mutations or expressions to select treatments likely to be most effective. Yet, despite its tangible benefits, the application of precision medicine, specifically in cancer care, still presents significant challenges. This approach can be expensive, invasive and time-intensive as tumors are analyzed through traditional pathology and genomics.

Increasingly, AI-enabled imaging presents a powerful opportunity to accelerate the identification and application of personalized treatments in ways that are often less invasive, faster and potentially more cost-effective. In the past few years, weve started to see several promising applications of AI in imaging to support precision medicine initiatives.

A study published in the Journal of Neuro-Oncology in April 2019 shows strong potential for using machine learning algorithms to reveal multimodal MRI patterns to accurately and rapidly predict the presence of genotypes and mutations in glioma specifically, isocitrate dehydrogenase (IDH) and 1p19q codeletion status which are good predictors of treatment efficacy.

There has also been substantial progress in AI screening for breast cancer, as shown in this recent study published by Nature in January 2020. These are just a few examples, and the potential for others is limitless.

There are a number of factors at play. First, in our daily lives, weve all come to expect unlimited access to information and services whether online or from our mobile phones. These expectations are now carrying over to our healthcare experience.

At last years HIMSS conference, Dr. Donald Rucker, national coordinator for health IT told attendees, Its long overdue for the healthcare industry to be a part of the smartphone economy and enable patients to access their health data through an app of their choice, at no additional cost.

Giving patients access to their data through mobile devices and apps can drive increased levels of patient engagement and better empower their decision-making. In line with expanding expectations for sharing data with patients, CMS has finalized a rule focused on streamlining patient access to health data.

It is also possible that patients expanded access to their health information might help to fuel nascent interest in crowdsourcing of chronic disease data, which could someday present a wealth of information that clinicians and researchers have struggled to access easily.

HIMSS20: Follow us on Twitter as we gear up for the biggest health IT conference of the year in March.

Even as progress accelerates, the industry continues to face challenges as it works to unlock the greatest value from healthcare data. These include hurdles associated with interoperability, security and privacy as technologies advance faster than policy can keep pace.

Healthcare organizations and payers cannot afford to wait for perfection. Instead, they can make solid advances today that will enable them to accelerate at pace with patient expectations, regulations and technology. It all starts with a data foundation that can support the modern data experience that healthcare organizations and consumers crave.

Creating this new type of data experience requires a new type of data hub one that allows organizations to consolidate their systems on a single platform to unify and share data across applications for better insight. Rather than acting as merely a data repository, the data hub must be able to share and deliver data within an organization for modern analytics and AI so patients and clinicians can benefit from the analysis.

As we enter this data decade, the future is bright for healthcare organizations and the patients they serve. By embracing a modern data experience and building a foundation that ensures its success researchers, providers and payers will be well positioned to improve patient outcomes and elevate operational proficiency in the years to come.

Read more:
It's All About the Data in 2020 and Beyond - HealthTech Magazine

Read More...

The 3 Most Important Things to Know About Illumina’s Q4 Results – Motley Fool

Thursday, January 30th, 2020

A few days ago, I predicted that there would be few if any surprises with Illumina's (NASDAQ:ILMN) fourth-quarter results. This was an easy prediction to make: Illumina CEO Francis deSouza's presentation at the J.P. Morgan Healthcare Conference earlier this month included some sneak peeks at the company's Q4 performance.

Illumina announced its Q4 results after the market closed on Wednesday. I was right that there wouldn't be many surprises. But there was one twist. Here are the three most important things to know about Illumina's Q4 results.

Image source: Getty Images.

Illumina reported Q4 revenue of $953 million, up 10% year over year. This figure was well above the consensus analysts' revenue estimate of $942.9 million. However, Wall Street analysts made their Q4 projections prior to deSouza's presentation at the J.P. Morgan conference.

DeSouza told conference attendees that Illumina expected to report Q4 revenue of around $950 million. The company's actual revenue total came in slightly higher than that level.

Product revenue increased by 10% year over year to $812 million, with solid sales for NovaSeq and NextSeq. Services and other revenue rose by 9.3% year over year to $141 million. As anticipated, headwinds in the direct-to-consumer market weighed on Illumina's overall growth.

DeSouza didn't provide a hint about what Illumina's Q4 earnings would be. The average analysts' estimate projected that the company would generate adjusted earnings per share (EPS) of $1.58. Illumina handily beat that estimate, though, announcing Q4 adjusted EPS of $1.70 -- up nearly 29% year over year.

I wrote earlier this week, "If there's anything unexpected in Illumina's Q4 results, it will probably be related to expenses that impact the bottom line." And that's exactly where the one surprise in the company's quarterly update occurred.

Illumina's total operating costs were basically flat year over year thanks largely to an 8.5% decline in research and development expenses. This, combined with a $15 million reduction in cost of service and other revenue, helped boost the company's bottom line.

Illumina projects full-year 2020 revenue growth of between 9% and 11%. The company expects earnings per diluted share between $6.45 and $6.65 based on generally accepted accounting principles (GAAP), with non-GAAP EPS between $6.80 and $7.00.

The company's guidance didn't contain any surprises. DeSouza said at the J.P. Morgan conference that Illumina expected to deliver revenue growth in the 9% to 11% range for full-year 2020. Wall Street analysts were expecting full-year adjusted EPS to come in between $6.80 and $7.00, with the average analysts' estimate slightly above the midpoint of the range.

Francis deSouza said that Illumina's management believes "that this is the decade that genomics becomes available to cancer and genetic disease patients on a mass scale and integrates into standard of care." That view could very well be right.Genomic sequencing is a critical part of personalized medicine. Increasingly more new drugs are being developed that target specific types of cancer and that rely on sequencing.

Illumina's dominant position in the genomic sequencing market and its decades of leadership make it the player to beat in capitalizing on the growth that should be on the way. However, the company has some vulnerabilities, notably including its lack of expertise in long-read sequencing. The planned acquisition of Pacific Biosciences of Californiawould have addressed this issue, but it's now off the table.

Perhaps the biggest challenge for Illumina is that, as a growth stock, investors expect higher revenue and earnings growth than the company will be able to deliver over the short term. This could put a damper on the stock at least temporarily. But if deSouza's optimistic view of the future proves to be accurate and Illumina can deliver on its potential, the one-time high-flying stock should take off yet again.

Read this article:
The 3 Most Important Things to Know About Illumina's Q4 Results - Motley Fool

Read More...

Some helpful tips to survive and thrive at HIMSS20 – Healthcare IT News

Thursday, January 30th, 2020

Believe it or not, here we are: already just a month-plus away from the biggest and best health IT show in the world. It's time to formulate a plan of action.

The HIMSS Global Health Conference & Exhibition, which takes place March 9-13 at the Orange County Convention Center in Orlando, Florida.

HIMSS20, as veteran conference-goers know, offers a unique opportunity to spend a week hobnobbing with some 45,000 or so of your closest friends. It plays host to health IT professionals of all stripes: vendors, clinicians, health system executives, policymakers, military health leaders, patient advocates and other healthcare professionals from across the globe.

Its 300-plus education sessions offer not just continuing ed credits but invaluable perspectives and best practices from industry experts tackling the biggest challenges in healthcare. Its slate of well-known keynote speakers bring galvanizing words to spark inspiration. It social and networking opportunities are terrific opportunities to share and learn from innovative new ideas.

As veteran conference-goers also know, careful planning of one's time in Orlando is key to getting the most out of all that activity. With so much going on at once across the sprawling convention center, having a flexible but well-considered to-do list is essential.

Beyond some of the obvious points that are repeated each year wear comfortable shoes, as they will log many miles! here's some other advice and information to get the most from your conference experience.

For those heading to HIMSS20 for the first time, its guide for first time attendees is a must-read.

Among its key tips: Book hotels early! (HIMSS suggests making reservations through OnPeak, its official housing company.) HIMSS also offers an orientation webinar that will take place a week to 10 days before the show.

The HIMSS20 guide also offers other key advice: badge pickup, education certification, onsite information desk and complimentary shuttle service to hotels and the airport.

Full conference registration includes entry to the Monday night opening reception, all keynote and Views from the Top sessions, all general education sessions between March 10 and March 12, as well as access to the exhibition floor for those days.

But an extra fee gains access to a jam-packed day of preconference education and networking on Monday, March 9.

There are stalwarts such as the CHIME-HIMSS CIO Forum, the AMDIS/HIMSS Physicians Executive Symposium and the Nursing Informatics Symposium, of course.

But there are plenty of other daylong sessions to pique the interest of professionals from all corners of the healthcare space: aging technology and AI, big data and blockchain, cloud and consumerism and much, much more.

HIMSS20 gets started in earnest on Tuesday, March 10, with the opening keynote and discussion: Dr. Gianrico Farrugia, president and CEO of Mayo Clinic, George Halvorson, chair and CEO of the Institute for InterGroup Understanding and Dr. Rod Hochman, president & CEO, Providence St. Joseph Health will talk "Digital Health Transformation: The Path Forward."

Throughout the week, other big names scheduled to give keynotes include National Coordinator for Health IT Dr. Donald Rucker, CMS Administrator Seema Verma, former Governors Chris Christie and Terry McAuliffe and baseball great Alex Rodriguez.

When it comes to education sessions, there's no shortage of them. High-level View from the Top presentations will offer industry leaders discussing everything from AI to APIs, value-based care to virtual reality.

And the hundreds of other education session taking place during the week use this handy search function to find the ones most relevant for you cover nearly every topic imaginable: cybersecurity, interoperability, organizational change management, personalized medicine, population health, quality improvement, user experience, venture investment, and much more.

The beating heart of HIMSS20 will be the Exhibition Floor, with more than 1,300 vendors showing the latest in technology innovation, hundreds more targeted education sessions and more pedestrian traffic than some mid-sized cities. Plan your perambulation with this interactive map.

Attendees should also be sure to stop by any or all of the many Specialty Pavilions, such as the Career Expo, Cybersecurity Command Center, Debut Square, Innovation Live, University Row and, of course, the venerable Intelligent Health Pavilion and Interoperability Showcase.

Throughout the week, be sure to keep an eye on social media, too. HIMSS and Healthcare IT News will be offering a stream on new updates via Facebook and Twitter, so follow the hashtag #HIMSS20 for all the latest. Following the feeds of HIMSS' newest class of Digital Influencers is another great way to stay in the loop with all the latest buzz.

The official HIMSS Global Health Conference Mobile App expected to be made available in February is another must-download, with all the info on educational sessions, exhibitor listings, floor maps, news, networking opportunities and more.

And speaking of networking events there's a ton of them on tap for Orlando in March: an array of receptions, meet-ups, community events, HIMSS chapter confabs, the annual awards gala, and many more. See a full listing here.

HIMSS20 takes place March 9-13 at the Orange County Convention Center in Orlando.

Continued here:
Some helpful tips to survive and thrive at HIMSS20 - Healthcare IT News

Read More...

Could Colchicine Be the New Aspirin? – Medscape

Thursday, January 30th, 2020

This interview is a translation of a video discussion posted on Medscape France. It has been edited for clarity.

Michel Zeitouni, MD, MSc: Hello. I am Michel Zeitouni, a cardiologist at the Piti-Salptrire Hospital and a researcher with the organization ACTION Cur (Allies in Cardiovascular Trials, Initiatives and Organized Networks). Today I have the pleasure of welcoming Prof Jean-Claude Tardif to Medscape; we are speaking from the American Heart Association (AHA) 2019 meeting in Philadelphia, Pennsylvania.

Prof Tardif is the research director at the Montreal Heart Institute. He presented a study that made a lot of noise at the AHA, the COLCOT study. COLCOT included more than 4000 patients with myocardial infarction (MI) and found a reduction in cardiovascular events in those who received colchicine compared with the placebo group. Prof Tardif, tell us about the results.

Jean-Claude Tardif, MD: Colchicine is a potent anti-inflammatory drug, and there is an accumulation of data suggesting that inflammation is relevant to the progression of atherosclerosis. The COLCOT study included 4745 patients who were recruited within 30 days of their MI. They all received two antiplatelet agents and a statin, and they underwent angioplasty if necessary. Then they were assigned colchicine at a low dose of 0.5 mg/day or placebo. The average follow-up was 23 months, and we found a 23% reduction in the primary efficacy outcome, which was the combination of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring revascularization.

Zeitouni: The inflammation pathway has been in the spotlight ever since the CANTOS study, which used canakinumab, a drug that we have known well for decades and with which we found some benefits for patients with MI. You also looked at tolerability, since it's a question we ask about colchicine; ultimately, it was tolerated rather well.

Tardif: Perhaps it's in part because we used a low dose of 0.5 mg/day, but we saw no difference in the incidence of adverse effects of any cause or severity, and no difference in the occurrence of diarrhea compared with placebo. There was a very slight increase in nausea, with 1.8% in the active group vs 1.0% in the placebo group. There also was a little more pneumonia in the colchicine group (0.9% vs 0.4%).

Zeitouni: You used a rather broad composite endpoint and saw a consistent effect on each component. One thing that struck those who saw your presentation was colchicines effect on stroke. How do you explain the reduction in stroke? Do you anticipate a COLCOT STROKE study?

Tardif: I'm not sure I have all the answers, but we were not the first to see this. There was a meta-analysis of very small, previously published studies that also suggested a benefit for stroke. Now, is this an anti-atherosclerotic effect related to the anti-inflammatory effect of colchicine? Is it an effect that has something to do specifically with the cerebral arteries? Could there be unsuspected effects on central blood pressure? This remains to be seen. It opens up questions that have yet to be answered but deserve to be tested in clinical trials. So, yes, there will be clinical studies on colchicine in stroke.

Zeitouni: Someone mentioned COLCOT-2 in one of the late-breaking trials. Would you tell us about this trial? Colchicine will be used in primary prevention for diabetics.

Tardif: Exactly. Now that COLCOT-1 has been conducted in patients with a recent MI, there is another study called LoDoCo2, in patients with stable coronary disease, that will be presented in 2020. The next frontier will be the high-risk, primary-prevention patients in what we call COLCOT-T2D. This study will involve 10,000 patients with type 2 diabetes who do not have known coronary heart disease. We will assess cardiovascular efficacy, but we will also look at the occurrence of cancer, cognitive disorders, and dementia, because we will be following these patients for 4 years; the COLCOT-1 patients were followed for an average of 23 months.

Zeitouni: So, colchicine may be the new aspirin in these high-risk patients. You saw a reduction in infarct size in the acute phase or the time of remodeling, and a reduction, perhaps, in rhythm disorders. How do you explain the effectiveness?

Tardif: I believe that it is an anti-atherosclerotic effect via the anti-inflammatory effect. I say this because patients were, on average, 13 days post-MI. And when we look at the time at which the events occurthe effect on the stroke, the effect on urgent hospitalizations for anginait seems more related to the anti-atherosclerotic effect than to an effect on ventricular remodeling.

Zeitouni: Another study that was presented at AHA was COLCHICINE-PCI. Those investigators studied patients undergoing angioplasty, to learn whether the administration of colchicine reduced the rate of infarction or periprocedural myocardial damage. The outcomes assessed were biomarkers of myocardial injury. They did not find any difference in these markers, but they did find that inflammation decreased in the colchicine arm as measured by interleukin-6 levels. What are your thoughts on this? Is there a role for colchicine in angioplasty to reduce periprocedural events?

Tardif: The concept was interesting. I think there were, unfortunately, significant methodologic problems in COLCHICINE-PCI. First, the study included only about 400 patients, so the power was extremely limited. Second, the investigators chose to give only one dose of colchicine before angioplasty and not to repeat it afterwards. It was unlikely that we would see any significant longer-term effects. In contrast, COLCOT had not 400 but 4700 patients, and we treated the patients for 23 months. I am struggling to learn from COLCHICINE-PCI. If we want to repeat the experiment, we should do it with longer treatment duration. The finding of a reduction in periprocedural inflammation is the interesting part for me.

Zeitouni: With all of these results from COLCOT, are we a step further in the fight against the residual risk of our coronary patients. Which postinfarction patients would you treat and for how long?

Tardif: First, which patients? If you remember, at the trial presentation people were saying, "Oh, my goodness, are we now going to add another drug on top of the two antiplatelet agents, the statin, and maybe even an ACE inhibitor?" My answer is, really, is this the most intelligent way to practice medicine?

Zeitouni: It should be personalized.

Tardif: Exactly. Instead of saying, "We will give all medicines to everyone," why not try to tailor them by clinical characteristics? We will obviously do subgroup analyses in COLCOT. It is important to understand that not all the data were analyzed because it became available only a few weeks before the conference. We had put a manuscript together for the New England Journal of Medicine and for the AHA presentation. However, we have work to do in the coming months, analyzing the subgroups as well as others, looking at biomarkersis there a particular genetic profile that could show us the patients who would benefit from colchicine?

Personally, I think it's a bad idea to say that we will give six drugs to everyone. In some patients the disease will be mediated by inflammation, whereas in others it will be mediated by diabetes. So I believe it will be necessary to move toward personalized medicine.

Zeitouni: Precisely, with patients who have inflammation and progressive atherothrombotic disease, and occasionally with some young people, who also relapse despite optimal medical treatment. We have a drug now that is well tolerated, accessible, and with strong evidence.

Tardif: I think we could give it to everyone, but with any medications we give, we should make an effort to understand who in particular benefits.

As to your question about duration of treatment, the average follow-up was 23 months, so perhaps we should treat these patients for 2 years. As I noted, COLCOT-T2D will follow patients for 4 years, but for now I would recommend at least 2 years of treatment.

Zeitouni: Prof Tardif, thank you very much for your explanations and for this study, which will improve the prognosis of our patients. We now know more about inflammation and atherothrombosis, thanks to this type of research.

For more cardiology, follow us on Twitter

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See the article here:
Could Colchicine Be the New Aspirin? - Medscape

Read More...

Predictive Oncology Inc. Signs Letter of Intent to Acquire Quantitative Medicine (qtmed.com) and an AI Engine (CoRE) that Facilitates Accelerated Drug…

Thursday, January 30th, 2020

MINNEAPOLIS, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) ("Predictive Oncology" or "the Company"), a knowledge-driven company focused on applying artificial intelligence ("AI") to personalized medicine and drug discovery, today announces it has signed a letter of intent to acquire Quantitative Medicine (QM).

Dr. Carl Schwartz, president and CEO of Predictive Oncology, believes the synergies created by the acquisition, if completed, will help the Company accelerate the commercialization of its AI-driven technology and services, "By coupling QM's CoRE predictive modeling platform with our tumor profiling expertise and data we believe we can revolutionize the way precision therapies are developed, said Dr. Schwartz."

QM is a biomedical analytics and computational biology company, founded by Dr. Robert Murphy and Dr. Joshua Kangas, both of Carnegie Mellon University, that has developed a novel, computational drug discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs by predicting the main effects of drugs on target molecules that mediate disease.

Predictive Oncology's Helomics division has built an AI knowledgebase of drug response profiles from over 150,000 cancer cases, Using AI to leverage that data the information can now be integrated with CoRE to build robust predictive models of how specific types of tumors will react to cancer drug therapies.

"Our goal is to provide researchers in pharma, biopharma and diagnostic companies' with actionable insights that will not only drive the development of new precision therapies, companion diagnostics, and biomarkers, but will also help them design better targeted trials," concluded Schwartz. "Working together, we have the potential to dramatically improve patient outcomes." The transaction is expected to complete in Q1-2020.

Completion of the transaction, which is expected to be completed in the first two quarters of 2020, is subject to the negotiation of a definitive agreement and other terms and conditions.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ:POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics' CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to its clients' specific needs. Predictive Oncology's TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially "fools" cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis' Oncology Capture Technology Platforms which isolate and help categorize an individual patient's heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology's Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit http://www.predictive-oncology.com.

About Quantitative Medicine Inc.

Quantitative Medicine is a biomedical analytics and computational biology company offering a novel drug discovery platform which dramatically reduces the time, cost and financial risk of discovering new therapeutic drugs by predicting: the main effects of drugs on target molecules that mediate disease; the effects of drugs on other molecules or pathways in the body that could mediate adverse effects; as well as the interaction of these with underlying genetic variations. The platform identifies similarities in relationships of drug candidates screened against a diverse matrix of pathogenic, cellular, molecular and/or systems biology targets. By iteratively adding new data from other existing research or additional experiments, the predictive model is improved. More accurate predictions can be made for previously unobserved effects of putative compounds on target molecules. "Because of the complexity of biological systems, cutting-edge machine-learning methods will be critical for future drug discovery and development."www.qtmed.com

Forward-looking Statements

Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Risks and uncertainties relating to a transaction with Quantitative Medicine include no assurance that a transaction will be completed or, if completed, no assurance that the acquisition of Quantitative Medicine would result in anticipated benefits. Further, the acquisition could involve unanticipated costs, distractions to Company management or other risks or adverse effects, and any issuance of equity securities in the transaction would result in dilution to the Company's stockholders, which may be significant. Other risks and uncertainties regarding the Company's securities include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company's and Helomics' existing businesses, distraction of management and diversion of resources; and the market price of the Company's common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictive's ability to implement its long range business plan for various applications of its technology; Predictive's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictive's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the SEC, which are available for review at http://www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictive's financial position. See Predictive's most recent Annual Report on Form 10-K, and subsequent reports and other filings at http://www.sec.gov.

Contact:

Bob Myers651-389-4800bmyers@skylinemedical.com

Continue reading here:
Predictive Oncology Inc. Signs Letter of Intent to Acquire Quantitative Medicine (qtmed.com) and an AI Engine (CoRE) that Facilitates Accelerated Drug...

Read More...

SAGA Diagnostics Extends its Collaboration with Servier to Use Ultrasensitive SAGAsafe Technology in Cancer Clinical Trials – b3c newswire

Thursday, January 30th, 2020

LUND, Sweden, January 28, 2020 / B3C newswire / -- SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered service agreements with the international pharmaceutical company Servier, based in Paris, France.

These deals exemplify the increased demand we are experiencing for our offerings of ultrasensitive cancer analysis services and analysis kits. We are excited to be working with Servier, who continues to choose us for important translational oncology projects. Lao Saal, CEO of SAGA Diagnostics.

The collaboration will be covering a total of three preclinical/clinical studies and is scheduled to run for approximately two years. In the course of these projects, SAGA Diagnostics will be developing assays and performing liquid biopsy tests on patients from multiple Servier clinical studies using the SAGAsafe technology (formerly known as IBSAFE) to identify and quantify circulating tumor DNA (ctDNA).

SAGAsafe technology is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify mutations in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance to a limit of detection of ~0.001% mutant allele frequency. The analyses will be run in the SAGA Diagnostics central laboratory in Lund, Sweden.

We have been impressed by the service and ultra-sensitivity performance of SAGAsafes analyses and are looking forward to continue working together. Involving the SAGAsafe technology in these studies means that Servier will now be able to monitor effects at an earlier stage ensuring that we do not miss out on any insights. Brian Lockhart, Director of CentEx-Biotechnology, Servier.

SAGAsafe is part of a portfolio of ultrasensitive technologies, which also includes SAGAsign (formerly known as KROMA) for monitoring chromosomal rearrangements, as well as novel technologies in development. SAGA offers both off-the-shelf analysis services and kits as well as custom-tailored solutions to fit customers needs. SAGAs molecular tools are being used in clinical trials and hospitals for detecting actionable mutations, monitoring treatment response, measuring minimal residual disease, and identifying resistance mechanisms to help direct therapy.

About SAGA Diagnostics ABSAGA Diagnostics AB is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive liquid biopsies such as blood samples. With SAGAsafe and SAGAsign services and kits, SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and gives patients peace of mind.Follow us on Twitter@SAGAdiagnosticsandLinkedIn.

Contact

ke Nilsson, BD Director This email address is being protected from spambots. You need JavaScript enabled to view it.+46 733 01 72 42

Keywords: Circulating Tumor DNA; Neoplasm, Residual; Limit of Detection; Precision Medicine; Liquid Biopsy; Medical Oncology; Genetic Testing; Pharmaceutical Preparations

Published by B3C newswire and shared through Newronic

See the original post here:
SAGA Diagnostics Extends its Collaboration with Servier to Use Ultrasensitive SAGAsafe Technology in Cancer Clinical Trials - b3c newswire

Read More...

Genedata and the Crohn’s & Colitis Foundation Collaborate to Improve Patient Care in Crohn’s Disease – PR Web

Thursday, January 30th, 2020

This collaboration is helping us accelerate our search for precision biomarkers to prognosticate disease course and to guide early and effective personalized treatment decisions in Crohns disease patients.

BASEL, Switzerland (PRWEB) January 30, 2020

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful completion of a Data Science Services project in support of the Crohns & Colitis Foundations mission to advance precision medicines for Crohns disease and to improve patients quality of life. Researchers and clinicians collaborated with Genedata data scientists to integrate and analyze multi-omic and clinical data collected from large cohorts of patients with Crohns disease, to identify the most informative biomarkers that can be used to assess the risk to develop serious complications requiring surgery within five years after diagnosis. The combination of certain clinical parameters and specific omic biomarkers has the potential to lead to significant improvement in Crohns disease patient care.

The Crohns & Colitis Foundation, the leading non-profit organization focused on research and patient care in inflammatory bowel diseases (IBD) for over 50 years, serves as a hub for Crohns disease research with the largest collection of IBD patient data from institutions around the world. To achieve the goal of accelerating treatments and cures, the Crohns & Colitis Foundation looked for a partner to leverage the multitude of longitudinal clinical and molecular data from different omic technologies from large Crohns disease cohorts. In choosing Genedata as its partner to integrate and analyze their vast collection of clinical and high-dimensional molecular data, the Crohns & Colitis Foundation recognized the firms extensive domain expertise gleaned over more than 20 years, along with the benefits offered by its unique precision medicine software platform for translational and clinical research, Genedata Profiler. The Genedata team of expert bioinformaticians leveraged these resources to deliver actionable results that could be used to develop a diagnostic product.

Crohns disease is a chronic, often debilitating disease, for which there is currently no cure. Despite several treatment options, currently we lack predictive tests to determine the optimal treatment strategy early in the disease process, when the opportunity to improve outcomes is greatest. There is a significant unmet need to advance new diagnostic tools to enable precision medicine approaches and to optimize patient care according to the severity of the disease course, said Andrs Hurtado-Lorenzo, Ph.D., Senior Director of Translational Research at the Crohns & Colitis Foundation. We decided to implement cutting-edge data analysis methods to integrate clinical and genomic data from patients, as a strategy to advance our biomarker research efforts. We are pleased to have found in Genedata a trusted and reliable partner who provided us with expert knowledge in big multi-omic data analysis. This collaboration is helping us accelerate our search for precision biomarkers to prognosticate disease course and to guide early and effective personalized treatment decisions in Crohns disease patients.

Commenting on the successful completion of the recent project, the CEO of Genedata, Othmar Pfannes, Ph.D., said, The volume and complexity of multi-omic data together with clinical data is growingly rapidly and is challenging to analyze. Our Data Science Services together with our Genedata Profiler platform is set up to address this challenge and to enable our partners to make data-informed decisions on a per-project basis without having to build their own data infrastructure or hire data scientists. Dr. Pfannes continued, We are proud that our expertise has been helpful to the Crohns & Colitis Foundation.

About the Crohns & Colitis FoundationThe Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel diseases (IBD). The Foundations mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life for the more than 3 million Americans living with IBD. Its work is dramatically accelerating the research process through its database and investment initiatives; the Foundation also provides extensive educational resources for patients and their families, medical professionals, and the public. For more information, visit http://www.crohnscolitisfoundation.org, call +1-888-694-8872, or email info@crohnscolitisfoundation.org.

About GenedataGenedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US. http://www.genedata.comLinkedIn | Twitter | YouTube

ContactMiles Fisher-PollardGenedataPublic RelationsPhone: +41 61 511 85 61pr@genedata.com

DisclaimerThe statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:

See original here:
Genedata and the Crohn's & Colitis Foundation Collaborate to Improve Patient Care in Crohn's Disease - PR Web

Read More...

Intermountain Precision Genomics Announces Advancements in Personalized Cancer Care with Expanded TheraMap Test – Press Release – Digital Journal

Thursday, January 30th, 2020

This press release was orginally distributed by ReleaseWire

Salt Lake City, UT -- (ReleaseWire) -- 01/29/2020 -- Intermountain Precision Genomics continues to expand cancer testing through advancements to TheraMap, a test for advanced-stage cancer patients. The new TheraMap test expands the ability to examine a tumor's DNA to provide individualized treatment options.

Cancer is caused by changes in DNA that can make a normal cell become cancerous. Utilizing state-of-the-art genomic technology, TheraMap analyzes and interprets what changes, or gene mutations are present in a patient's tumor DNA.

With the ability to detect important mutation types across more than 500 genes relevant to cancer treatment, relevant gene fusion events including NTRK fusions, and important microsatellite instability (MSI) and tumor mutational burden (TMB) biomarkers, TheraMap results can be used to personalize treatment for each patient.

In addition to its significant gene panel, another feature that sets TheraMap aside from other cancer tests is the molecular tumor board, a multi-institutional group of clinical experts and precision medicine leaders who review the solid tumor results and provide oncologists with recommendations for specific therapies and treatments.

"Our unique process analyzes the genetic makeup of a patient's cancer and employs a team of skilled Molecular Tumor Specialists to review each solid tumor test and determine how to most effectively treat that cancer case," said Lincoln Nadauld, MD, PhD, oncologist and chief of Precision Health and Genomics at Intermountain Healthcare. "Our team approach gives oncologists confidence, information, and support they need to prepare a customized, targeted treatment plan for each patient."

When compared to traditional diagnostic tests and treatment, TheraMap's methods provide significantly better results for patients at lower overall healthcare costs something patient Jeffery Layne appreciates.

In January 2018, Layne was diagnosed with stage four kidney cancer that had spread to other parts of his body and was told that he would have six months to two years to live. Layne's oncologist, Derrick Haslem, MD, associate medical director for the Intermountain Healthcare Oncology Clinical Program, recommended that he try TheraMap.

"The TheraMap test helped to determine exactly what gene mutations were causing Mr. Layne's cancer, allowing us to create an individualized plan for him," said Dr. Haslem.

Utilizing TheraMap's results, Dr. Haslem discovered Layne would be a good candidate for immunotherapy treatment, a personalized infusion that boosts the body's own immune system to fight cancer.

Layne showed a quick response to the treatment with masses under his arms shrinking almost immediately. After just two months of immunotherapy, the masses disappeared and tumors on his lungs were significantly smaller.

"They've come so far in being able to diagnose the problems related to cancer, it's just amazing," said Layne. "As a cancer patient, watching all the progress in precision medicine and cancer research is really encouraging."

Two years later, Layne continues to improve while painting and spending time with his grandkids. View more about Jeffrey Layne's story.

"Intermountain Precision Genomics is pleased with the advances in TheraMap that will continue to help our advanced-cancer patients see better results, which are longer lives and overall improved quality of life," said Dr. Nadauld.

Visit intermountainhealthcare.org/abouttheramap for more information about TheraMap testing.

About Intermountain Precision GenomicsIntermountain Precision Genomics is transforming healthcare by targeting treatment to deliver the highest quality care at some of the lowest costs in the nation, all while helping people live the healthiest lives possible. Intermountain Precision Genomics is a service of Intermountain Healthcare, a system widely recognized as a leader in clinical quality improvement and efficient healthcare delivery. For more information about Intermountain Precision Genomics, please visit intermountainhealthcare.org/genomics.

For more information on this press release visit: http://www.releasewire.com/press-releases/intermountain-precision-genomics-announces-advancements-in-personalized-cancer-care-with-expanded-theramap-test-1273295.htm

Link:
Intermountain Precision Genomics Announces Advancements in Personalized Cancer Care with Expanded TheraMap Test - Press Release - Digital Journal

Read More...

Precision Health Informatics and Concerto HealthAI to Collaborate on Advanced Precision Medicine Solutions – Yahoo Finance

Monday, January 20th, 2020

Concerto HealthAI's Real-World Data analytical capabilities will enable Precision Health Informatics to accelerate innovation in cancer testing and treatment

DALLAS and BOSTON, Jan. 14, 2020 /PRNewswire-PRWeb/ --Concerto HealthAI, the market leader for Real-World Data (RWD) and enterprise AI technology, announced today an agreement with Precision Health Informatics, a subsidiary of community-based cancer care pioneer Texas Oncology, to accelerate the advancement of precision medicine to treat cancer patients. Precision Health Informatics will work with Concerto HealthAI to advance RWD solutions, research studies, and AI-enabled technologies focusing on genomic and molecular characterization of patient disease to develop effective new therapies to treat some of the most challenging and devastating cancers.

Precision Health Informatics will leverage Concerto HealthAI's eurekaHealth 3.0 enterprise AI solution to advance precision medicine solutions for clinical research. Using AI models to enrich clinical data, Precision Health Informatics will more quickly derive insights from patient data to inform new study designs or identify eligible patients for clinical studies. Precision Health Informatics joins an expanding set of Concerto HealthAI's Real-World Evidence collaborators, such as theAmerican Society of Clinical Oncology's CancerLinQ relationship announced in late 2017.

"Precision Health Informatics' model uses information from the molecular profile representing the genetics of the patient's disease combined with the clinical information specific to that patient to develop personalized medicine solutions that are integral to diagnosing cancer and offering physicians and patients effective treatment options," said Lori Brisbin, Vice President for Precision Health Informatics, "Concerto HealthAI's leadership in solutions for precision medicine will help us derive more meaningful insights from patient data, that in turn may help us connect patients with appropriate clinical trials."

"Using data from Texas Oncology's large patient base, Precision Health Informatics is at the forefront of precision medicine, innovative cancer testing and diagnostic approaches, such as Next Generation Sequencing changing and improving the standard of care for patients. Ultimately, this is all about developing and connecting cancer patients to precise, effective treatment," said R. Steven Paulson, MD, President of Precision Health Informatics, and President and Chairman of Texas Oncology. "Concerto HealthAI's deep expertise in research-grade RWD solutions and AI technologies make it the ideal collaborator with Precision Health Informatics to help us more quickly develop medical innovations that benefit patients in our practice and elsewhere."

"At Concerto HealthAI, we seek clinical collaborators committed to advancing insights and new treatment strategies for patients with the highest unmet medical needs," said Jeff Elton, PhD, CEO of Concerto HealthAI. "Precision Health Informatics is making a deep commitment to enabling precision medicine, which we see as highly complementary to the work of our biomedical innovator partners."

This collaboration will advance novel research solutions, integrating deep clinical insights derived from electronic medical record data, particularly information about the molecular basis of disease derived from tissue or liquid samples. The value of these insights in helping connect patients to effective treatment options will be made available to Texas Oncology patients through its precision medicine program.

About Concerto HealthAI Concerto HealthAI is a technology leader in Definitive Real-World Data (RWD) and AI solutions for Precision Oncology. Our mission is to bring together unique data assets, leading AI-based technologies, and the world's top outcomes research and data science talent. Our focus is on revolutionizing clinical and outcomes research to accelerate the insights benefitting patient treatment. For more information, visit us at http://www.concertohealthai.com.

About Precision Health Informatics and Texas Oncology Precision Health Informatics, a subsidiary of Texas Oncology, is a precision medicine solutions company that uses patients' genetic information for innovative testing, diagnostics, and treatment of cancer. Precision Health Informatics' solutions are based on data-driven insights from a vast, diverse patient base. Texas Oncology is an independent private practice with more than 460 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 90 FDA-approved therapies, about one-third of all cancer therapies approved to date. For more information, visit http://www.texasoncology.com.

MEDIA CONTACTS

Jen Toole Concerto HealthAI 617.779.1828 jtoole@shiftcomm.com

Ed Bryson Texas Oncology 512.592.8190 edward.bryson@usoncology.com

SOURCE Concerto HealthAI

More here:
Precision Health Informatics and Concerto HealthAI to Collaborate on Advanced Precision Medicine Solutions - Yahoo Finance

Read More...

Moderna Partners with AWS to Explore the ‘Software of Life’ – BioSpace

Monday, January 20th, 2020

The software of life. Thats how Stephane Bancel, the chief executive officer of Moderna, described messenger RNA (mRNA), which is at the core of Modernas drug development process.

Moderna is pioneering mRNA drugs that are believed to be able to direct the body to produce any protein of interest, including antibodies and other proteins that can create therapeutic activity. Bancel said mRNA is an information molecule.

Its like software, he said.

The company, which has secured enormous investments over the past few years, is inching closer to being a commercial company in developing personalized therapies for a wide range of diseases, including cancer. In order to create those personalized medicines, the Cambridge, Mass.-based company relies on gene sequencing and a partnership with one of the worlds largest companies Amazon.

In an interview with CNBCs Jim Cramer during the J.P. Morgan Healthcare Conference this week, Bancel said the company relies on Amazon Web Services to compare every letter of DNA in the sequencing process. Once that is done, the company can deduce what needs to be done to develop personalized medicine, Bancel explained.

Amazon Web Services, the fastest growing division of the company, according to CNBC, provides on-demand cloud computing platforms to companies. Moderna is currently using Amazon Web Services with more than a dozen drug candidates in its pipeline, which means the high-tech platform plays a central role in the companys drug development program. As CNBC explains, the company is using the powerful cloud-based service to speed up the time it takes a drug candidate to move from the preclinical to the clinical phase. In addition to Moderna, Amazon Web Services is being used by several pharmaceutical companies, including San Diego-based Human Longevity Inc., Regeneron Pharmaceuticals and more.

The reliance on the high-speed program could lead to the company finally becoming a commercial entity 10 years after it was launched. Last week, just ahead of JPM, Bancel pointed to one of the companys clinical candidates as a potential blockbuster, an experimental treatment for cytomegalovirus (CMV), the most common infectious cause of birth defects in the United States.

Moderna said the analysis following a Phase I trial, which was taken after the third and final vaccination, shows continued boosting of neutralizing antibody titers in patients. The mRNA-based vaccine, mRNA-1647, is designed to protect against CMV infection. Cytomegalovirus is a common pathogen and is the leading infectious cause of birth defects in the United States with approximately 25,000 newborns in the U.S. infected every year. CMV is passed from the mother to her unborn child. Birth defects occur in about 20% of infected babies. The defects can include neurodevelopmental disabilities such as hearing loss, vision impairment, varying degrees of learning disability and decreased muscle strength and coordination. There is no approved vaccine to prevent CMV infection.

In October, the company received Fast Track Designation from the U.S. Food and Drug Administration for mRNA-3927, its investigational mRNA therapeutic for propionic academia, which is caused by the inability of the body to breakdown certain proteins and fats which leads to the build-up of toxic chemicals. Moderna plans to initiate an open-label, multi-center, dose-escalation Phase I/II study of multiple ascending doses of mRNA-3927 in primarily pediatric patients.

Read the original:
Moderna Partners with AWS to Explore the 'Software of Life' - BioSpace

Read More...

Is Cloud Computing the Answer to Genomics Big Data… – Labiotech.eu

Monday, January 20th, 2020

The success of the genomics industry has led to generation of huge amounts of sequence data. If put to good use, this information has the potential to revolutionize medicine, but the expense of the high-powered computers needed to achieve this is making full exploitation of the data difficult. Could cloud computing be the answer?

Over the last decade, genomics has become the backbone of drug discovery. It has allowed scientists to develop more targeted therapies, boosting the chances of successful clinical trials. In 2018 alone, over 40% of FDA-approved drugs had the capacity for being personalized to patients, largely based on genomics data. As the percentage has doubled over the past four years, this trend is unlikely to slow down anytime soon.

The ever-increasing use of genomics in the realm of drug discovery and personalized treatments can be traced back to two significant developments over the past decade: plunging sequencing costs and, consequently, an explosion of data.

As sequencing technologies are constantly evolving and being optimized, the cost of sequencing a genome has plummeted. The first sequenced genome, part of the Human Genome Project, cost 2.4B and took around 13 years to complete. Fast forward to today, and you can get your genome sequenced in less than a day for under 900.

According to the Global Alliance for Genomics and Health, more than 100 million genomes will have been sequenced in a healthcare setting by 2025. Most of these genomes will be sequenced as part of large-scale genomic projects stemming from both big pharma and national population genomics initiatives. These efforts are already garnering immense quantities of data that are only likely to increase over time. With the right analysis and interpretation, this information could push precision medicine into a new golden age.

Are we ready to deal with enormous quantities of data?

Genomics is now considered a legitimate big data field just one whole human genome sequence produces approximately 200 gigabytes of raw data. If we manage to sequence 100M genomes by 2025 we will have accumulated over 20B gigabytes of raw data. The massive amount of data can partially be managed through data compression technologies, with companies such as Petagene, but that doesnt solve the whole problem.

Whats more, sequencing is futile unless each genome is thoroughly analyzed to achieve meaningful scientific insights. Genomics data analysis normally generates an additional 100 gigabytes of data per genome for downstream analysis, and requires massive computing power supported by large computer clusters a feat that is economically unfeasible for the majority of companies and institutions.

Researchers working with large genomics datasets have been searching for other solutions, because relying solely on such high-performance computers (HPC) for data analysis is economically out of the question for many. Large servers require exorbitant amounts of capital upfront and incur significant maintenance overheads. Not to mention, specialized and high-level hardware, such as graphics processing units, require constant upgrades to remain performant.

Furthermore, as most HPCs have different configurations, ranging from technical specs to required software, the reproducibility of genomics analyses across different infrastructures is not a trivial feat.

Cloud computing: a data solution for small companies

Cloud computing has emerged as a viable way to analyze large datasets fast without having to worry about maintaining and upgrading servers. Simply put, Cloud computing is a pay-as-you-go model allowing you to rent computational power and storage. and its pervasive across many different sectors.

According to Univa the industrial leader in workload scheduling in the cloud and HPC more than 90% of organizations requiring high performance computing capacity have moved, or are looking into moving to the cloud. Although this is not specific for companies in the life sciences, Gary Tyreman Univas CEO suggests that pharmaceutical companies are ahead of the market in terms of adoption.

The cloud offers flexibility, an alluring characteristic for small life science companies that may not have the capital on-hand to commit to large upfront expenses for IT infrastructure: HPC costs can make or break any company. As a consequence, many opt to test their product in the cloud first, and if numbers look profitable, they can then invest in an in-house HPC solution.

The inherent elasticity of cloud resources enables companies to scale their computational resources in relation to the amount of genomic data that they need to analyze. Unlike with in-house HPCs, this means that there is no risk money will be wasted on idle computational resources.

Elasticity also extends to storage: data can be downloaded directly to the cloud and removed once the analyses are finished, with many protocols and best practices in place to ensure data protection. Cloud resources are allocated in virtualized slices called instances. Each instance hardware and software is pre-configured according to the users demand, ensuring reproducibility.

Will Jones, CTO of Sano Genetics, a startup based in Cambridge, UK, offering consumer genetic tests with support for study recruitment, believes the cloud is the future of drug discovery. The company carries out large data analyses for researchers using its services in the cloud.

In a partnership between Sano Genetics and another Cambridge-based biotech, Joness team used the cloud to complete the study at a tenth of the cost and in a fraction of the time it would have taken with alternative solutions.

Besides economic efficiency, Jones says that moving operations to the cloud has provided Sano Genetics with an additional security layer, as the leading cloud providers have developed best practices and tools to ensure data protection.

Why isnt cloud computing more mainstream in genomics?

Despite all of the positives of cloud computing, we havent seen a global adoption of the cloud in the genomics sector yet.

Medley Genomics a US-based startup using genomics to improve diagnosis and treatment of complex heterogeneous diseases, such as cancer moved all company operations to the cloud in 2019 in a partnership with London-based Lifebit.

Having spent more than 25 years at the interface between genomics and medicine, Patrice Milos, CEO and co-founder of Medley Genomics, recognized that cloud uptake has been slow in the field of drug discovery, as the cloud has several limitations that are preventing its widespread adoption.

For starters, long-term cloud storage is more expensive than the HPC counterpart: cloud solutions charge per month per gigabyte, whereas with HPC, once youve upgraded your storage disk, you have no additional costs. The same goes for computing costs: while the cloud offers elasticity, Univas CEO Tyreman says that the computation cost of a single analysis is five times more expensive compared to an HPC solution in many scenarios. However, as cloud technologies continue to progress and the market becomes increasingly more competitive among providers, the ongoing cloud war will likely bring prices down.

Furthermore, in the world of drug discovery, privacy and data safety are paramount. While cloud providers have developed protocols to ensure the data is safe, some risks still exist, for example, when moving the data. Therefore, large pharmaceutical companies prefer internal solutions to minimize these risks.

According to Milos, privacy remains the main obstacle for pharmaceutical companies to fully embrace the cloud, while the cost to move operations away from HPCs is no longer a barrier. While risks will always exist to a certain extent, Milos highlighted that the cloud allows seamless collaboration and reproducibility, both of which are essential for research and drug discovery.

Current players in the cloud genomics space

Cloud computing is a booming business and 86% of cloud customers rely on three main providers: AWS (Amazon), Azure (Microsoft) and Google Cloud. Although the three giants currently control the market, many other providers exist, offering more specialized commercial and academic services.

Emerging companies are now leveraging the technology offered by cloud providers to offer bioinformatics solutions in the cloud, such as London-based Lifebit, whose technology allows users to run any bioinformatics analyses through any cloud provider with a user-friendly interface effectively democratizing bioinformatics for all researchers, regardless of skill set.

Federation is a concept from computing now used in the field of genomics. It allows separate computers in different networks to work together to perform secure analysis without having to expose private data to others, effectively removing any potential security issues.

The amount of data organizations are now dealing with has become absolutely unmanageable with traditional technologies, and is too big to even think about moving, explained Maria Chatzou Dunford, Lifebits CEO and co-founder.

When data is moved, you increase the chances of having it be intercepted by third-parties, essentially putting it at significant risk. Data federation is the only way around this unnecessary data storage and duplication costs, and painstakingly slow data transfers become a thing of the past.

Getting ready for the genomics revolution

Its no secret that genomics is key to enabling personalized medicine and advancing drug discovery. We are now seeing a genomics revolution where we have an unprecedented amount of data ready to be analyzed.

The challenge now is: are we ready for it? To be analyzed, big data requires massive computation power, effectively becoming an entry barrier for most small organizations. Cloud computing provides an alternative to scale analyses, while at the same time, facilitating reproducibility and collaboration

While the cost and security limitations of cloud computing are preventing companies from fully embracing the cloud, these drawbacks are technical and are expected to be resolved within the next few years.

Many believe that the benefits of the cloud heavily outweigh its limitations. With major tech giants competing to offer the best cloud solutions a market valued at $340 billion by 2024 we might be able to expect a drastic reduction in costs. While some privacy concerns may still exist, leading genomics organizations are developing new tools and technologies to protect genomic data.

Taken as a whole, it is likely that the cloud will be increasingly important in accelerating drug discovery and personalized medicine. According to Univas Tyreman, it will take around 1015 years to see the accelerated transition from HPC to cloud, as large organizations are often conservative in embracing novel approaches.

Distributed big data is the number one overwhelming challenge for life sciences today, the major obstacle impeding progress for precision medicine, Chatzou Dunford concluded.

The cloud and associated technologies are already powering intelligent data-driven insights, accelerating research, discovery and novel therapies. I have no doubt we are on the cusp of a genomics revolution.

Filippo Abbondanza is a PhD candidate in Human Genomics at the University of St Andrews in the UK. While doing his PhD, he is doing an internship at Lifebit and is working as marketing assistant at Global Biotech Revolution, a not-for-profit company growing the next generation of biotech leaders. When not working, he posts news on LinkedIn and Twitter.

Images via E. Resko, Lifebit and Shutterstock

See the article here:
Is Cloud Computing the Answer to Genomics Big Data... - Labiotech.eu

Read More...

Leadership in the Age of Personalization is About Creating Healthy Environments So People Can Thrive – Forbes

Monday, January 20th, 2020

This is Part 8 of an eight-part series featuring thought-provoking insights from theLeadership in the Age of Personalization Summit. Here is Part 1, Part 2, Part 3, Part 4, Part 5, Part 6 and Part 7.

All Employers are in the Business of Health

My definition of harmony is when your head, your heart, your feet, and your gut are all going in the same direction.

I love that quote. In the context of business, we could think of the head as your strategy, the heart as your vision, the feet as your operating model and forgive the metaphor the gut as your source of fuel. Its where your resources churn and create the energy that makes everything else possible.

In other words, its your people.

Are your head, heart, feet and gut in harmony? Or, more likely, is your gut a little upset? Off balance? Irritated?

Think about how difficult it is to get anything done when your actual, physical gut is irritated. A large organization is the same. You can have a bold vision, a smart strategy, an effective operating model. But if your people are feeling stifled, not activated to their fullest potential, or bogged down by physical, emotional or financial health issues, none of that other stuff will make a difference.

In my last article, part 7 of this series, we heard from healthcare leaders. But the reality is were all in the business of health. No matter your industry, the physical, mental and financial health of your employees and their families affects your bottom line and your ability to thrive as an organization. The health of your customers and the communities you serve also affect the scope of the impact you can have.

How does this fit into this series of articles on our societys transition from an age of standardization to our current age of personalization? Heres a story that might help connect the dots.

A few years ago I met with some C-level executives at a company. I made a bold prediction: You probably have someone at the executive level who has a chronic disease or cares for someone with a chronic disease that is not covered by your insurance. They're probably struggling to get by, even with an executive salary."

Most respectfully disagreed with my prediction. But one person at the table scribbled a note and the CEO said: "Looks like I'm wrong." There was a VP who was living out of his car because he was paying for his mother's cancer and a grandparents diabetes.

If were leading in a way that honors this age of personalization, everything about that scenario should change. Ill leave it to the experts to fix our system so caring for sick family members wont cost so much. But we can at least we can create workplace cultures that dont make someone feel like they must hide such hardships from their peers.

We need systems in place for getting to know people as individuals. People shouldnt be afraid to discuss health issues related to physical or mental health. If they are afraid, youve got a problem.

In its Mental Health at Work 2019 Report, Mind Share Partners shares results from surveying 1,500 people in the United States: nearly 60% of respondentsreported symptoms of a mental health condition in the past year; and almost 60% of people never talked to anyone at work about their mental health in the last year. No wonder: when conversations about mental health did occur, less than half were described as a positive experience. One result? Youll lose good people. According to the survey, 50% of millennials, 75% of Gen Z-ers and 34% overall had left roles for mental health reasons, both voluntarily and involuntarily.

How do we as leaders open ourselves up so that people will be comfortable to be in their most vulnerable state?

This subject was tackled at the Leadership in the Age of Personalization Summit, where senior leaders from industries spanning healthcare, automotive, finance, consumer packaged goods, retail, technology, apparel and more, gathered to explore the tension were all feeling in this shift from standardization to personalization.

Throughout the day we discussed building economies of scale around human dignity, how to escape the extremes to achieve balance, how assimilation destroys individuality and inclusion restores it, how to allow personalized values to influence your brand identity, Wall Streets perspective on how companies are not prepared for what is about to hit them, how a companys mission is worthless without individual contribution and the importance of what you measure.

Tending to Employees Mental Health

Stephanie Neuvirth is the Senior Vice President of People and Organization at Banfield Pet Hospital.

She said Banfields people strategy is its business strategy, because to keep growing as a company they need to attract and retain more healthcare professionals a goal made more challenging by the cost of veterinary school and high levels of compassion fatigue among practitioners.

The pet space is growing at double digit growth, she said. As we look at the growth of our business and the trajectory over the next 10 years, and then look at the supply of the individuals in our space, candidly, the biggest concern to our growth strategy is our ability to find and keep great talent.

Stephanie Neuvirth and Gyasi Chisley during their panel discussion at the Leadership in the Age of ... [+] Personalization Executive Summit.

Banfield leaders believe theres a connection between Banfields commitment to preventive health for pets and its commitment to the health and energy of employees (whom they call associates). They deal with many of the same challenges as people in human healthcare do.

We see very high levels of compassion fatigue, high levels of suicide, high levels of burnout, said Neuvirth. What we see is a very serious and concerning situation about the profile of the individuals that go into our profession. They tend to be perfectionists. They are burdened with tremendous student debt. All of these things combined make it a very, very challenging environment.

Banfields health & wellbeing approach encompasses five areas: body, mind, finances, career and community.

We believe that all five parts are very important, and it's a different combination for every single person, said Neuvirth. For some, their biggest stressor is financial. For others its about not feeling connected to community. For others, it really is about not getting the career growth that they're looking for. So we're focused on how we bring all five parts to life and how to solve for the various combinations.

Ive written in the past about Banfields Veterinary Student Debt Relief Program (read about it here): Managing Employee Stress, Debt, and Emotional Turmoil in the Age of Personalization.

The nations largest general veterinary practice is also putting particular attention and resources behind mental health, addressing the suicide epidemic head-on.

According to the CDC, one in six veterinarians has considered suicide, said Neuvirth. Those are staggering and very concerning numbers. In 2018, we hired a mental health professional and are looking at partnering with social workers, not just for our client experience but for our associates.

She said they recently rolled out a first-of-its kind suicide prevention training for veterinary professionals called ASK Assess, Support, Know.

ASK is intended not only to support our own associates, but also to give them tools to spot emotional distress and suicidal thoughts in their colleagues, she said. In addition to making the ASK e-learning available to all 19,000+ Banfield associates nationwide, we also closed schedules at all of our 1,000+ Banfield hospitals for two hours to offer an interactive mental health and wellbeing training.

And theyre sharing the ASK training and resources with the industry.

As one of the largest employers in the veterinary health space, we feel a responsibility to support the entire profession, said Neuvirth. In observance of the harrowing 1-in-6 statistic, we made ASK available to the entire profession, including U.S. vet schools, on January 6, 2020.

That last part is so important: finding creative solutions and then sharing them with others.

In past articles Ive talked about discovering what you solve for as an individual what you solve for is what you consistently think about in a big way, the problems you are typically drawn to, and the kinds of solutions you favor. But it also applies to organizations.

One of the things Banfield is solving for is suicide awareness and prevention among healthcare professionals, and theyve created a method that can be used by others facing similar challenges. This is what can happen when you start tending to your gut and put individuals at the center of your strategy.

Making Cancer Care More Precise

Going back to healthcare in particular, one of our biggest challenges is to make sure our increasing levels of personalized care are accessible to all people. Next Ill share the personalization of cancer care from the viewpoint of a physician providing the care and then an executive of an organization expanding access to care.

Dr. Joseph Alvarnas is Vice President of Government Affairs, Senior Medical Director for Employer Strategy, and Associate Clinical Professor in the Department of Hematology/Hematopoietic Cell Transplantation at City of Hope.

He described how this tension between personalization and standardization has actually changed paradigms of care.

I'm a cancer care provider, he said. We've entered an era of precision medicine. So, things that we would have thought about as one cancer a decade ago when you look at them very closely on a genetic level, you realize they represent hundreds of different of sub-types of cancer.

He said there are about 22,300 genes in the human genome.

That's the entire instruction set to make, maintain, sustain a human being over the course of our lives, he said. Sometimes those genes go wrong in very, very particular ways. We're learning about these things at a pace that I would never have imagined years ago, and we're seeing innovations directed at very specific genetic mutations in cancer.

Dr. Alvarnas speaks at the Leadership in the Age of Personalization Executive Summit.

This idea that we can understand the genetic nature of someone's cancer, identify the exact correct therapeutic, and bring it to that individual in a timely, efficient, rapid way, said Dr. Alvarnas, so that we don't give wrong care, we mitigate unnecessary toxicities, we get that person well, keep them home, get them back to life that's actually real. That's the precision and personalized medicine paradigm for delivering care.

Talk about personalization. But he also posed this challenge: How do you create a system of high through-put knowledge understanding, and then marshal it to the needs of a patient in a family in a highly personalized way?

Because cancer care is not a technological experience, it's a human experience, said Dr. Alvarnas. We don't treat diseases. We care for patients and their families, because families are as responsible for good outcomes as any of the most critical elements of what we do.

Then he made the connection to employers.

Employers are invested in this, because not only do employers bear the costs for misadventures in care, but they also bear witness to the human consequences of what it's like to have an employee or a family member, or someone who's aligned with your company, go through a cancer journey.

Making Cancer Care More Accessible

Just as each cancer is different, so is each persons cancer journey.

Gyasi Chisley is another healthcare executive working hard to make those journeys as personalized as possible. He is President of Hospitals and Clinics for Cancer Treatment Centers of America (CTCA), a national comprehensive cancer care network with five hospitals around the country and a growing footprint of Outpatient Care Centers and other locations.

CTCA has been around for about 32 years, and its founder Richard J. Stephenson had the notion of creating a patient empowerment platform. Chisley said 82% of their patients live below the Federal Poverty Line. He said consumers come directly to them, usually for a second opinion, which means theyre often out-of-network.

A lot of the folks that were suffering from cancer or had that evil diagnosis were, number one, scared, and then number two, didn't have an opportunity to get that second opinion, said Chisley. So we started expanding through a footprint of what we call OIS, which is Oncology Information Systems just to get information out there directly to the patient. And that's been happening for 32 years.

They also took a holistic approach.

Our chairman had the foresight to say let's treat the patient holistically, with things like massage and acupuncture almost regardless of cost because we think thats better in the long run, said Chisley. But even more, what are the patient's goals? What are they really trying to achieve?

Chisley said one of the things theyre working on is going direct to employer, and having those crucial conversations with employers that will help them look at their workforce planning and look for opportunities for interventions that will ensure that the continuum of care is top of mind.

Glenn Llopis and Gyasi Chisley during their fireside chat at the Age of Personalization Executive ... [+] Summit.

We're not the most popular people in the payer's eyes these days we're doing things like having diet consults, we're doing things that are out of the box, if you will, for new cutting-edge clinical trials, and not always getting reimbursed from the payer, said Chisley. But you know what that is demonstrating? It's demonstrating to the employer that we're taking care of their people, and that's why we're going direct to employer and direct to consumer. So, that's opportunity for us, not only to be evolutionary, but revolutionary.

Chisley said after a day of hearing executives talk about personalization at the summit, hes inspired to dig even deeper as a leader: We see our patients come in at their most vulnerable times, particularly with this despicable disease of cancer. I've been vulnerable, but I haven't been vulnerable enough. And that's opportunity for me to be humble and make sure we're meeting our patients where they are.

An Appeal From Gen Z

Meeting people where they are. Thats what this age of personalization is all about.

After a full day of C-level leaders sharing their experiences and being vulnerable with each other, we closed the summit with a different kind of VIP your current customer, your future employee and, frankly, your future leader.

Brielle Lubin is in 8th grade. She describes herself as born from a Jewish-American father and a Japanese mother from Tokyo. She is very proud of her Jewish-American culture and is equally proud of her Japanese culture. At her school in Los Angeles she leads two clubs: the Gender Sexuality Awareness Club and the Asian American Cultural Club.

Throughout the day of the summit, she had been playing piano in the background. When she addressed the audience from the stage at the end of the day, she did it with the confidence of someone who already gives thought and action to these ideas of personalization.

Heres just a sampling of what she shared with us:

As a part of the youth community, we're always told, You have no idea what you're talking about. That's so ridiculous. That's frivolous. You're too young.

I may not be the CEO of a company like everyone else here. I'm just some 14-year-old kid. But you know what? When we're told when we're younger, Hey, you can be yourself, you can express your opinion, there are places where people can talk to you and help you I find that to be the most important thing. Because we cannot start assimilating when were young, if [our goal is to] avoid assimilating when we're older.

Brielle Lubin speaks at the Leadership in the Age of Personalization Executive Summit.

Everyone is a different shade of a color in the entire color spectrum. None of us is exactly the same. There's always some sort of shade that's just a little bit off, and that's the most important thing and we need to acknowledge that because identity crisis occurs the most when we don't recognize that difference, when we think we need to blend with other colors.

When people try to paint something, they don't just blend every single color of the rainbow together. They use all the colors individually, use them as a different shade on a different part of the paper, and that's what we are. We are all that different shade of a color on that paper.

Welcome to the Age of Personalization

Consider what Brielle said. This is the thinking thats already entering your workforce today, and will be in full force within your organizations in the next 10 years.

If youre not already trying to create the systems that allow for this level of inclusive leadership, you will not remain relevant in a marketplace where consumers and employees value their individuality.

The luxury of time is over, and I want to leave you with this sense of urgency. Throughout this series we have explored the difference between leadership in the age of standardization and in the age of personalization. But this is just the beginning.

Knowing something is right isnt enough to start doing it. And knowing something is wrong isnt enough to stop doing it.

We are a nation burning out at work not just because were working so hard and so much, but because were doing that without any sense of who we are and any connection to what we are doing. Engaged or not, the negative forces of standardization have stripped so many of us of our identities.

Only by rediscovering who we are as individuals and embracing that individuality in others can we find our purpose and contribute to a healthier whole.

Leadership in the age of personalization is about creating healthy environments we can all thrive in. It is the force that will push us to start over again. I see this as the beginning of a movement. And now the question is: what are you going to do about it?

Read more from the original source:
Leadership in the Age of Personalization is About Creating Healthy Environments So People Can Thrive - Forbes

Read More...

Scientists Discover 4 Distinct Patterns of Aging – Livescience.com

Monday, January 20th, 2020

Some people's hearts stay strong well into their 60s, but their kidneys begin to fail. Others may have the kidneys of a 30-year-old but fall victim to constant infection.

Now, scientists may be one step closer to understanding why the aging process varies so drastically between people.

Even within a single person, aging unfolds at different rates in different tissues, sometimes striking the liver before the heart or kidney, for example. People fall into distinct categories depending on which of their biological systems ages fastest, and someday, doctors could use this information to recommend specific lifestyle changes and design personalized medical treatments, according to a new study, published Jan. 13 in the journal Nature Medicine.

The research team behind the study sorted 43 people into aging categories, or "ageotypes," based on biological samples collected over the course of two years. The samples included blood, inflammatory substances, microbes, genetic material, proteins and by-products of metabolic processes. By tracking how the samples changed over time, the team identified about 600 so-called markers of aging values that predict the functional capacity of a tissue and essentially estimate its "biological age."

So far, the team has identified four distinct ageotypes: Immune, kidney, liver and metabolic. Some people fit squarely in one category, but others may meet the criteria for all four, depending on how their biological systems hold up with age.

"Now, it's going to be a lot more than just four categories," said senior author Michael Snyder, a professor and the chair of genetics at the Stanford University School of Medicine in California. For instance, one participant in the study appeared to be a cardiovascular ager, meaning their cardiac muscle accumulates wear-and-tear at a greater rate than other parts of their body. "If we [surveyed] 1,000 people, I'm sure we'll find other cardio agers and that category will become better defined." And with more research, even more patterns of aging may emerge, Snyder added.

Related: 8 Tips for Healthy Aging

In the past, scientists have hunted for markers of aging in enormous datasets for large populations, Snyder, told Live Science. Researchers pinpointed markers of aging by comparing data from young people to that of older people, but for individuals, that kind of data captures only a specific moment in time. It cannot reveal how a given person might change as they age, Snyder said.

In a clinical setting, that means population-based markers might not be the best measure to determine how a patient is aging, or what combination of medical treatments might suit them best, he added.

"Population-based decisions are crude at best," Synder said. They won't necessarily hold up for you, per se."

By tracking specific people through time, Snyder and his co-authors hoped to learn how aging markers differ between individuals. Their study participants ranged in age from 29 to 75 and provided at least five biological samples over the course of two years. Even within that relatively short time frame, several patterns of aging emerged.

For example, immunological agers accumulated more markers of inflammation through time, while metabolic agers accrued more sugar in their blood, indicating that their bodies were metabolizing glucose less efficiently. Similar to scores on a personality test, each individual's aging "profile" included a combination of traits, mixed and matched from different ageotypes.

Snyder and his co-authors plan to follow the study participants to see how their aging profiles morph over time. They also aim to develop a simple ageotype test that could be used in the doctor's office to quickly assess a patient's health status, and potentially point them toward the best possible treatment options.

"There are drugs and various kinds of dietary interventions and lifestyle interventions through which it may be possible to modulate some of these aging processes," Dr. James Kirkland, a gerontologist and head of the Kogod Center on Aging at the Mayo Clinic in Rochester, Minnesota, told NBC News.

"But in order to apply those correctly, we have to know which people to apply which drugs or which dietary interventions in order to get the most bang for the buck," said Kirkland, who was not involved in the new study.

Related: 7 Ways the Mind and Body Change With Age

While existing drugs, diets and exercise regimes can target some signs of aging, other markers aren't fully understood yet.

For example, over the course of Snyder's study, a marker of poor kidney function decreased in 12 individuals, eight of whom took statins. The marker, a waste product called creatinine, accumulates in the blood as muscle tissue naturally breaks down, but the kidneys typically filter the substance and expel it through the urine. Creatinine levels fell in the eight individuals on statins, suggesting that the medication improved their kidney function, though it's unclear why levels also dipped in four additional people, the authors noted.

The team also found that concentrations of several microbes seem to change with age, but we don't yet know how that may affect health. Certain microbes may proliferate in response to age-related changes in the body, while others help drive them, Snyder said. The authors also spotted differences in how diabetic and pre-diabetic people aged as compared to insulin-sensitive people, but it's unclear whether these markers indicate meaningful differences in health status. Many studies suggest that insulin plays a central role in aging throughout the animal kingdom, but more research is needed to clarify its exact influence over human aging.

For now, ageotypes present as many questions as they do answers about human aging. Until scientists understand what various aging markers really mean, clinicians will continue to rely on standard vital sign assessments to track patients' health over time. In the near future, perhaps ageotypes could serve to motivate people to take better care of areas of their body that appear to be aging faster than others, Snyder said. For instance, if someone fits the profile of a cardiovascular ager, they might focus on improving their cardiovascular health and undergoing relevant medical tests to check on their progress.

"As we collect a lot more information, we are going to be better able to follow how people are aging, [as well as] what interventions they did that actually reduced their aging," Snyder said.

Originally published on Live Science.

The rest is here:
Scientists Discover 4 Distinct Patterns of Aging - Livescience.com

Read More...

Artificial Intelligence Expert Neil Sahota Says AI Will Have Major Impact On 2020 Elections And In Medicine – Yahoo Finance

Monday, January 20th, 2020

Sahota Offers AI Predictions for the New Year

LOS ANGELES, Jan. 15, 2020 /PRNewswire/ --Artificial intelligence, or AI, will play a significant role in the 2020 election campaign and may also lead to major breakthroughs in solving personal medical issues, according to futurist and AI expert Neil Sahota.

"I'm increasingly concerned about the impact of fake news, photo scams and other deceits designed to negatively influence voting this year," says Sahota, who works closely with the United Nations and other organizations to foster innovation and develop next generation products/solutions to be powered by AI. "We will see the effect of more AI tools generating fraudulent information and influencing voters. Thankfully, there will also be new tools to fight this kind of disinformation. What is certain is that machine vs machine battles will become more prevalent."

The author of the influential book Own the AI Revolution (McGraw Hill), Sahota is also an IBM Master Inventor, who led the IBM Watson Group and is a professor at the University of California/Irvine.

In addition to its potential impact on the election campaigns, Sahota predicts AI will be responsible for significant medical advances. "We will see more use of AI that will accelerate solutions for doctors, nurses, clinicians and researchers in providing personalized care," he said. "Each of us is genetically unique and there isn't a one-size fits all solution for us. But AI can solve this dilemma by providing personalized medicine based on a specific person's genomic sequence, lifestyle, medical history, environment and other differences. I think there will be great strides in these areas in the coming year."

"The election and medicine are only two areas where we will feel the impact of AI, which is coming into its own as an emerging technology," Sahota says. "We are likely to see it help combine tools such as block chain, virtual reality and artificial reality. For example, I envision a virtual reality courtroom where a law student interacts with an AI 'judge,' opposing counsel and jury. AI simulation is not only more 'real world' but has great variability, meaning each time the VR module is used, it's different. There's no memorization or 'cheat sheet' for the law student. It's a dynamic, highly interactive learning module and 2020 will start the wave of convergence: combining these technologies together.

About Neil Sahota: Neil Sahota is a futurist and leading expert on Artificial Intelligence (AI) and other next generation technologies. He is the author of Own the AI Revolution (McGraw Hill) and works with the United Nations on the AI for Good initiative. Sahota is also an IBM Master Inventor, former leader of the IBM Watson Group and professor at the University of California/Irvine. His work spans multiple industries, including legal services, healthcare, life sciences, retail, travel, transportation, energy, utilities, automotive, telecommunications, media, and government.

View original content:http://www.prnewswire.com/news-releases/artificial-intelligence-expert-neil-sahota-says-ai-will-have-major-impact-on-2020-elections-and-in-medicine-300987177.html

SOURCE Neil Sahota

Originally posted here:
Artificial Intelligence Expert Neil Sahota Says AI Will Have Major Impact On 2020 Elections And In Medicine - Yahoo Finance

Read More...

GSK, Pfizer contradict on the future of consumer health JV report – Endpoints News

Monday, January 20th, 2020

SAN FRANCISCO Few CEOs tell a story better than bluebirds Nick Leschly.

He cuts a Jeff Bezos figure on stage at the Colonial Room, the JP Morgan presentation hall for A-list biotechs: lean and bald, fast-talking and vest-wearing. He explains in simple language, apologizing when he has to brush on the data. It helps that he has a good story to tell.

We treated them one time, Leschly tells a packed crowd, gesturing to the slide behind him. Look what happened.

The slide shows 9 horizontal bars studded with diamonds. Each bar, he explained, represented a sickle cell patient, and each diamond represented a severe medical event, such as a pain crisis. The diamonds stud one side before the therapy and vanish on the other, afterward.

A 99% reduction in these events this is a functional cure for sickle cell disease, Leschly says. This is unprecedented data.

Upstairs and an hour later, Ted Love stands before a narrow conference room in his suit and polka-dot tie. Love, the CEO of Global Blood Therapeutics, is a 60-year-old physician. His voice trails off at the end of sentences, and the story he tells is less compelling. There are no cured patients.

This is the first drug that addresses the root cause of sickle cell disease, Love says, speaking in front of a slide showing a white pill bottle for GBTs new drug Oxbryta. Right in the label, it says that this drug inhibits polymerization.

In the 60 years after scientists discovered the cause of sickle cell, almost no treatments emerged, even as the condition debilitated hundreds of thousands of Americans, most of them black or Hispanic. But the last few years have seen a resurgence of interest as new technologies have made the disease seem newly beatable.

Unlock this story instantly and join 70,000+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

See the original post here:
GSK, Pfizer contradict on the future of consumer health JV report - Endpoints News

Read More...

How Perthera is Using AI and Molecular Data to Bring Precision Medicine to Oncology – DocWire News

Friday, January 10th, 2020

Perthera is a cancer therapeutic intelligence company that leverages Artificial Intelligence (AI) and data-driven therapy recommendations for oncologists to offer precisely tailored treatments to cancer patients based on their genetic factors, molecular profile and much more. The company was founded seven years ago by a team of experts in oncology, biomarkers, bioinformatics, and AI, and has since become a prominent force in bringing precision medicine to oncology. Read on to hear what Gary Gregory, Perthera CEO and President, had to say to DocWire Newsregarding his companys innovative work.

Gary noted that Pertheras primary goal is to harness all the benefits and opportunities of precision medicine in oncology. He added that the patients entire medical and treatment history, as well as their unique, multi-omic molecular profile position, is factored into the Perthera Platform, which is used by the physician to create their customized treatment plan. The patients comprehensive clinical information is run through the companys Therapeutic Intelligence EngineTM, which includes multiple databases, heuristic rules, algorithms and AI, that ultimately delivers a ranked set of therapeutic recommendations that the patients physician can consider. The AI built into the Perthera Platform leverages its computational engine and multiple databases to compile and utilize real-world evidence (RWE) to improve patient outcomes.

We also run each and every patient through our patented, cloud-based, molecular tumor board that allows us to scale a unique and powerful solution, Gary added. This contrasts with most cancer centers where less than 10% of patients typically have the benefit of a molecular tumor board, which has been proven to be highly advantageous from a medical practice perspective.

Another facet of Pertheras mission is to equip pharma, biotech, drug development companies and clinical trial organizations (CROs) with real-world evidence and clinical services that can enable them to expedite drug development, enhance market surveillance of these drugs and accelerate their clinical trials enrollment.

Regarding the advancement of their current technology, Gary noted that the company is always striving to advance Pertheras proprietary algorithms, use of real-world evidence, deployment of AI, and integration of new molecular technologies to continually improve their precision oncology solution.

Were also involved in a number of exciting projects with industry, whether its with pharma companies, CROs or advocacy groups, he added. We partner with them to bring forward their initiatives, the developmental work theyre doing on new therapeutic agents, theyre detailing the clinical efficacy of precision medicine, and even the clinical utility of Pertheras Platform, which has been proven to provide a significant improvement in both overall and progression-free survival.

Pertheras main offering is a Precision Medicine Program for Hospitals and Physicians, which allows healthcare providers to harness and capitalize on the benefits of Pertheras precision oncology platform. This program starts with the physician ordering the Perthera Platform and clinical report. Perthera completely de-burdens the clinical staff by orchestrating all molecular profiling tests, and running the comprehensive clinical information through its Therapeutic Intelligence EngineTM, and then an expert Molecular Tumor Board, consisting of a variety of medical experts, to ultimately produce the ranked therapeutic options.

Next, Perthera delivers a personalized report that is precisely matched to each patient, and contains specific, ranked therapeutic recommendations that are supported by medical, clinical, and scientific evidence, to promote expanded progression-free survival and overall survival outcomes.

The final step in this process involves Pertheras following the patient and capturing comprehensive RWE data regarding the patients treatment and outcomes.

And the physicians and hospitals can use this data for research purposes, whether its for publications, for accelerating their own clinical trials, or simply to advance the care of their patients, Gary explained. The data we collect is made available for their use. We provide it back to them via a dedicated portal so that they can take full advantage of the understanding, analysis and utilization of their specific data, to advance their practice of medicine and care of their patients.

Its also important to note that Perthera now customarily delivers their Platform at low to no charge to hospitals, physicians and patients. This approach has been transformative in allowing many healthcare organizations to capitalize on the Perthera Platform and all it offers to providers and patients.

The computational engine, or Therapeutic Intelligence EngineTM, is at the center of what Perthera offers healthcare providers and patients. This is founded upon their proprietary, comprehensive computational system that Perthera has been building over the course of six plus years.

It features 10 distinct databases and over 50,000 heuristic rules, algorithms and AI, he explained. Every patients data is analyzed by Pertheras Therapeutic Intelligence EngineTM. We provide an initial set of computationally ranked therapies, and then the patients clinical data and information is analyzed and polished by our expert, cloud-based, Molecular Tumor Board which provides the highly unique human in the loop component of our Platform. The byproduct of these elements is the Perthera Report, which has these precisely ranked therapeutic recommendations (including on label, off label and clinical trial options) for the physician to evaluate, choose from and direct their patients medical therapies. As we collect RWE outcomes and treatment selections, we incorporate that data back into our Therapeutic Intelligence Engine, which gains experience over time, to further improve our service and the resulting clinical outcomes.

As previously mentioned, research has shown that if the top-ranked therapies that Perthera suggests are chosen, survival rates are significantly more likely to be improved.

Beginning his work with Perthera in the past year, Gary noted that one of the first things he saw in the company was their proven approach to precision oncology, that was backed by reputable clinical research publications.

Our Platform and service is clinically proven in the sense that its been delivered to over 250 cancer centers and utilized by well over 10% of practicing oncologists across the U.S., he explained. Its also proven through peer-reviewed publications that detail when physicians use the Perthera Platform, they do a better job of harnessing the power of precision medicine and they improve their patient outcomes, both from an overall and progression-free survival.

Its a really exciting clinical arena and marketplace. The care of cancer patients is being transformed before our eyes. As importantly, its an exciting time for Perthera, because we believe were the only company that offers this end to end Platform, that has been proven to advance the care of patients, and also to deliver better clinical outcomes, he concluded. The comprehensive, end-to-end nature of what we do makes Perthera highly unique, and allows us to deliver exceptional value to patients, physicians, hospitals and biopharma companies.

Link:
How Perthera is Using AI and Molecular Data to Bring Precision Medicine to Oncology - DocWire News

Read More...

Page 30«..1020..29303132..40..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick